Safety and Efficacy of the Multitargeted Receptor Kinase Inhibitor Pazopanib in the Treatment of Corneal Neovascularization by Amparo, Francisco et al.
Safety and Efficacy of the Multitargeted
Receptor Kinase Inhibitor Pazopanib in the
Treatment of Corneal Neovascularization
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Amparo, Francisco, Zahra Sadrai, Yiping Jin, Belen Alfonso-
Bartolozzi, Haobing Wang, Hasanain Shikari, Joseph B. Ciolino,
et al. 2013. “Safety and Efficacy of the Multitargeted Receptor
Kinase Inhibitor Pazopanib in the Treatment of Corneal
Neovascularization.” Investigative Opthalmology & Visual Science 54
(1) (January 17): 537. doi:10.1167/iovs.12-11032.
Published Version doi:10.1167/iovs.12-11032
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34428165
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Clinical Trials
Safety and Efficacy of the Multitargeted Receptor Kinase
Inhibitor Pazopanib in the Treatment of Corneal
Neovascularization
Francisco Amparo,1 Zahra Sadrai,1 Yiping Jin,1 Belen Alfonso-Bartolozzi,1 Haobing Wang,1
Hasanain Shikari,1 Joseph B. Ciolino,1 James Chodosh,1 Ula Jurkunas,1
Debra A. Schaumberg,2 and Reza Dana1
PURPOSE. To evaluate the safety and efficacy of topical pazopanib
in the treatment of corneal neovascularization (CNV).
METHODS. Twenty eyes of 20 patients with stable CNV were
enrolled in a prospective, open label, noncomparative study and
treated with topical pazopanib 0.5% for 3 weeks, and followed
for 12 weeks. The primary endpoint was to determine the
tolerability and safety of topical pazopanib in the treatment of
CNV defined by the occurrence of ocular and systemic adverse
events during the study. The secondary endpoint was to
evaluate the effect of topical pazopanib on the reduction of
(1) neovascular area (NA), defined as the area of the corneal
vessels themselves, (2) invasion area (IA), defined as the fraction
of the total cornea into which the vessels extend, (3) vessel
length (VL), defined as the mean measurement of the extent of
vessels from end to end, and (4) vessel caliber (VC), defined as
the mean diameter of the corneal vessels.
RESULTS. There were no severe adverse events following the use
of topical pazopanib. Compared with the baseline visit, NA and
VL showed a statistically significant decrease at week 3 (P ¼
0.02 and 0.01, respectively); and NA, IA, and VL statistically
significantly decreased at week 12 (P¼ 0.03, 0.04, and <0.01,
respectively). Visual acuity maintained without changes after
the 12 week follow-up.
CONCLUSIONS. This preliminary study suggests that topical
treatment with pazopanib 0.5% is safe, well tolerated, and
may have a role as an alternative for the treatment of CNV
(ClinicalTrials.gov number, NCT01257750). (Invest Ophthal-
mol Vis Sci. 2013;54:537–544) DOI:10.1167/iovs.12-11032
Corneal neovascularization (CNV) as a result of vesselinvasion from the limbal arcade to the normally avascular
cornea is caused by a wide variety of common pathologic
conditions such as infection, trauma, and loss of the limbal
stem cell barrier.1,2 CNV plays an important role in induction
of allo-immunity3 and leads to the loss of the ocular immune
privilege; one of the strongest risk factors worsening the
prognosis of penetrating keratoplasty.4–6 Moreover, postoper-
ative ingrowth of neovessels into the avascular recipient bed is
a strong trigger to prompt graft rejection.7
Neovascularization is mediated by a diverse array of cellular
and molecular factors.8–10 Members of VEGF-A, B, C, and D are
key mediators in the development of neovessels.11 In the
cornea, the main sources of VEGF are epithelial cells, vascular
endothelial cells, macrophages, and fibroblasts.12 VEGF expres-
sion is significantly upregulated in the inflamed and vascularized
corneas. VEGF-triggered effects mediated via tyrosine kinase
receptors (VEGFR1, 2, 3) increase growth, migration, and
survival of the endothelial cells.13,14 VEGF blockade inhibits
CNV and promotes corneal graft survival.15–17 Platelet-derived
growth factor (PDGF), a dimeric glycoprotein, is also an
important mediator in neovascularization (NV). PDGF, via
tyrosine kinase PDGF receptors (a and b), stimulates VEGF
transcription and also plays an important function in pericyte
recruitment to neovessels. Sprouting endothelial cells secrete
PDGF, and pericytes express PDGFR-b; thus, inhibition of the
PDGF signaling pathway disrupts pericyte recruitment. This is
important, since endothelial cells without pericyte support and
VEGF signaling undergo apoptosis.17–24
The critical role of non-VEGF factors in suppressing NV has
indirectly been supported by previous studies, which have
shown that anti-VEGF therapy alone is not very effective in
regression of mature vessels that have developed as a result of
pathologic angiogenesis.25,26
These observations have led to the hypothesis that the
combination of VEGF and PDGF signaling inhibition may be
maximally effective in promoting vessel regression in patho-
logic ocular NV.27
Pazopanib (GlaxoSmithKline, King of Prussia, PA), is a small
multi-tyrosine kinase inhibitor (TKI) that targets VEGF and
PDGF receptors and inhibits angiogenesis.28,29 Pazopanib was
first approved by the Food and Drug Administration (FDA) for
the treatment of advanced renal cell carcinoma and more
recently for treatment of soft tissue sarcoma.30,31 Preclinical
data indicate that pazopanib may have potential ocular
applications. Inhibition of laser-induced choroidal NV has
been observed following oral administration of pazopanib,
consistent with inhibition of the VEGF and PDGF pathways.32
Formulated as an eye drop, pazopanib has been shown to
inhibit laser-induced choroidal NV,33 diabetic retinal vascular
leukostasis, and leakage in experimental models,34 and is under
clinical investigation for the treatment of neovascular AMD.
In this study, we evaluated the clinical safety and efficacy of
topical pazopanib for the treatment of established CNV. To our
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knowledge, this is the first study reporting the effects of topical
pazopanib on CNV.
METHODS
Design
Prospective, open label, noncomparative, phase I/II study.
Setting
This study was approved by the institutional review board and
conducted at the Cornea Service of the Massachusetts Eye and Ear
Infirmary, Boston, Massachusetts, and adhered to the tenets of the
Declaration of Helsinki.
Patient Selection
Twenty eyes of 20 with CNV were included in the study. Only patients
with clinically stable CNV that extended at least 1-mm beyond the
limbus were considered for enrollment. If both eyes were eligible for
the study, the most affected eye was selected. Clinically stable CNV was
established by excluding patients with: (1) ocular infection in the
previous month, (2) ocular surgery on the studied eye within the
previous 3 months, (3) contact lens use within the past 2 weeks, (4)
persistent corneal epithelial defect (>1 mm) within the past 3 months
that lasted 14 days or longer, and (5) full thickness or lamellar
keratoplasty within the past 3 months. Additional exclusion criteria are
listed in Table 1. All patients provided written informed consent before
the start of the study.
Treatment Protocol
All patients were provided with pazopanib 0.5% solution (Glaxo-
SmithKline) and were instructed to instill one drop four times per day
in the study eye for 3 weeks. Patients were instructed to continue with
their usual ophthalmic medication regimens. The superior and inferior
puncta of the study eye were plugged for the duration of the treatment
to minimize systemic drug absorption.
Follow-up Protocol
Study visits were scheduled at baseline and weeks 1, 3, 7, and 12. A
detailed review of the medical history and a complete ocular
examination that included Snellen visual acuity measurement, and
slit-lamp biomicroscopy were performed during each visit. Digital
corneal photography (IM-900; Haag-Streit, Koeniz, Switzerland) was
performed at baseline and weeks 3, 7, and 12. Systolic and diastolic
blood pressures were recorded at every visit. Blood samples were
taken during screening and week 3 to monitor liver function, complete
cell blood counts, and thyroid stimulating hormone.
Outcome Measures
Safety. Drug safety was evaluated by closely monitoring the
occurrence of ocular and systemic adverse events throughout the
study period. Ocular adverse events were assessed through complete
ocular examinations that included measurement of visual acuity, IOP,
and pachymetry. Systemic adverse events were evaluated with
patient questioning, vital signs monitoring (blood pressure and heart
rate), and laboratory testing: complete blood count, thyroid-
stimulating hormone, and liver function tests (AST, ALT) on the
scheduled visits.
Efficacy. The primary efficacy outcome measures were the size
and extent of CNV. The efficacy of topical pazopanib treatment on CNV
was evaluated by comparing corneal photographs acquired at baseline
with photographs acquired on the follow-up visits. Secondary efficacy
outcome measures of pazopanib were central corneal thickness and
best-corrected visual acuity. Size and extent of CNV was investigated by
four primary metrics: (1) neovascular area (NA), the area of the corneal
vessels when they are projected into the plane of a photograph, (2)
invasion area (IA), the fraction of the total corneal area into which the
vessels extend, (3) vessel length (VL), the total length of the vessels
projected into the cornea, and (4) vessel caliber (VC), the mean
diameter of the corneal vessels.
Our approach to NV quantification was detailed previously,35 and
only slightly modified. Briefly, using graphics editing software
Photoshop CS2 (Adobe Systems Inc., Berkeley, CA) and a plug-in
written in Java for ImageJ 10.2 (National Institutes of Health,
Bethesda, MD), we delimited the corneal area and enhanced blood
vessel visibility using color filters, then manually traced and pixelated
them for quantification. Invasion area was assessed connecting the
end of all vascular sprouts in order to define the contour of the
corneal area taken by neovessels. The measured invasion area was
expressed as a ratio of the total corneal area. Total vessel length and
mean caliber were calculated using the skeletonization function in
Amira 5 (Visage Imaging, San Diego, CA). This function automatically
extracts the pixel-skeletons of the vessels preserving the extent and
connectivity of the vascular structures, then calculating the distance
mapping of the vessels (total length) and average vessel thickness
(vessel caliber).
Statistical Analyses. To assess changes in the parameters
measured we considered all time points: (1) the initial (screening)
visit, (2) the 3 week visit (end of treatment), (3) the 7 week visit, and
(4) the last follow-up visit (12 week). Double-tailed Wilcoxon matched-
pairs signed rank test or paired t-tests were used to compare the
baseline values with each time point. The hypothesis for safety was
that topical pazopanib does not induce significant changes on baseline
parameters. The hypothesis for the efficacy metrics was that topical
pazopanib reduces the scores of a given metric from the baseline time
TABLE 1. Exclusion Criteria
 Uncontrolled hypertension* (systolic blood pressure of ‡150 mm
Hg or diastolic blood pressure of ‡90 mm Hg).
 History of clotting disorder* (including predisposition to
hypercoagulation or any previous thromboembolic event).
 Uncontrolled diabetes mellitus* (hemoglobin A1c >7%).
 Renal, liver, and coagulation abnormalities including current
anticoagulation medications other than aspirin.
 Current or recent (1 month) systemic corticosteroid therapy or
periocular corticosteroid injections to the study eye.
 Recent (2 week) change in dose and frequency of topical steroids,
nonsteroidal anti-inflammatory agents, or received intravitreal or
periocular steroids within 4 weeks prior to study entry.
 Ocular or periocular malignancy.
 Women 45 years of age or younger that are of child bearing
potential.
 Full thickness or lamellar keratoplasty within 90 days prior to
study entry.
 Recent (3 months) or planned surgery.
 Persistent epithelial defect (>1 mm and ‡14 days duration) within
2 weeks prior to study entry.
 Corneal or ocular surface infection within 30 days prior to study
entry.
 Received any other investigational therapy or treatment with anti-
VEGF agents (intraocular or systemic) within 60 days prior to
study entry.
 Soft contact lens (excluding bandage contact lens) use within 2
weeks prior to study entry.
 Any condition (including language barrier) that precludes patient’s
ability to comply with study requirements including completion of
study.
* To minimize the risk of potential adverse events.
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point to the subsequent time points in a statistically significant (defined
as P < 0.05) manner.
RESULTS
Twenty eyes of 20 patients with stable CNV were included in
the study. Patients (14 males and 6 females) had a mean age of
54.2 6 4.3 years at baseline. Table 2 shows the demographic
characteristics of the studied cohort. For safety (primary)
outcome measures, 20 patients were included in the analysis.
For efficacy (secondary) outcome measures, photographs from
only 18 patients were included in the statistical analysis, since
two patients experienced unexpected clearing of corneal
exudates that unveiled central CNV that had not been visible
below the previous exudates in the baseline photographs.
Values are presented as mean 6 SE.
Primary Outcomes
Safety. No unexpected ocular or systemic adverse events
were reported during the treatment or follow-up periods,
including eye examinations, vital signs, or patients’ reports. All
laboratory parameters remained unchanged from baseline to
the 3 week visit. Mean arterial pressure (MAP; [(2 3 diastolic
blood pressure) þ systolic blood pressure] ‚ 3) remained
unchanged at all follow-up visits when compared with
baseline. MAP was 92.0 6 1.7 mm Hg at baseline, 92.27 6
2.0 mm Hg at week 1 (P¼ 0.91), 90.7 6 1.4 mm Hg at week 3
(P¼0.44), 92.2 6 1.8 mm Hg (P¼ 0.92) at week 7, and 93.3 6
2.0 (P ¼ 0.56) at week 12. Other safety parameters, including
heart rate, pachymetry, and IOP, did not experience significant
changes (Table 3).
The most commonly reported adverse event was unilateral
tearing secondary to punctal occlusion in 10 (50%) patients.
Adverse events directly related to drug instillation included
transitory stinging in four patients (22%), dryness sensation in
one patient (6%), and blurred vision after drug instillation in
one patient (6%). None of the patients reported these events in
more than two visits.
Visual Acuity. To analyze the effect of pazopanib on visual
acuity, the Snellen visual acuity values were converted to their
LogMAR equivalents. At the baseline visit the mean corrected
LogMAR visual acuity was 1.03 6 0.25, 1.22 6 0.29 at week 3,
1.14 6 0.27 at week 7, and 1.08 6 0.23 at week 12. Compared
with the baseline visit, there were no statistically significant
changes at any of studied time points (P¼ 0.74, 0.73, and 0.19,
respectively).
Secondary Outcomes
Efficacy. Neovascular Area. At week 3 (end of treatment)
there was a statistically significant reduction in the NA of 14.3%
(1.0 6 0.5 mm2; P¼ 0.02) compared with baseline. At week 7
a reduction of 12.9% (0.9 6 0.7 mm2; P¼ 0.32) was noted. By
week 12 (end of the follow-up period) there was a statistically
significant reduction of 22.4% (1.5 6 0.8 mm2; P ¼ 0.03; Fig.
1A). Overall, 67% of patients experienced some degree of
response to therapy, with a mean decrease of 37.5% of the NA
in this subgroup.
Invasion Area. When compared with baseline, IA contract-
ed 9.7% (2.8 6 1.7 mm2; P¼ 0.09) and 6.7% (2.0 6 1.4 mm2; P
TABLE 2. Study Population Demographics
Patient Sex Age, y Diagnosis Additional Medications
HSV/HZO Keratitis
1 M 66 HZO keratitis 1, 7
2 F 80 HZO keratitis 2, 3
3 F 72 HSV keratitis 1, 4
4 M 35 HSV keratitis, corneal ulcer 1, 2, 7
5 M 24 HSV keratitis 1, 2, 3, 7
6 F 71 HSV keratitis None
7 F 74 HZO keratitis, bacterial ulcer 1, 2, 5
Keratoplasty/Failed Graft
8 M 59 Aphakic bullous keratopathy, PKP 2, 5
9 F 66 Traumatic cataract, PBK 1, 2, 3, 5, 7
10 M 41 Fungal keratitis, PKP 3, 6
11 M 41 Microbial ulcer, PKP 3, 7
12 M 38 Microphthalmia, sclero-cornea 5
13 F 56 Corneal perforation, keratoconus 1
Limbal Stem Cell Deficiency
14 M 79 Limbal stem cell deficiency 1, 2, 5, 6
Pterygium
15 M 77 MGD, rosacea, DES, recurrent pterygium 1
Trauma
16 M 44 Trauma, corneal scarring 1
17 M 68 Traumatic corneal perforation 5
18 M 35 SLK 1
19 M 29 Stevens-Johnson syndrome 1, 3
20 M 27 Rosacea, chronic blepharitis 2
HZO, herpes zoster ophthalmicus; HSV, herpes simplex virus; PKP, penetrating keratoplasty; PBK, Pseudophakic bullous keratopathy; MGD,
meibomian gland dysfunction; DES, dry eye syndrome; SLK, superior limbic keratoconjunctivitis; 1, Artificial tears; 2, Topical steroid; 3, Topical
antibiotic; 4, Oral antiviral; 5, Topical antiglaucoma; 6, Topical cyclosporine; 7, Oral antibiotics.
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¼ 0.18) at weeks 3 and 7, respectively. By week 12, a
statistically significant reduction of 13.3% (3.9 6 1.8 mm2; P¼
0.04) was achieved (Fig. 1B). In this metric 72% of the patients
responded to treatment, with a mean contraction of IA of
23.1%.
Vessel Length. At the 3 week visit there was a reduction of
20.0% in VL (32.9 6 13.8 mm; P ¼ 0.01) as compared with
baseline. At week 7 VL reduced by 17.0% (27.1 6 16.5 mm; P
¼ 0.11) and, by week 12 a statistically significant reduction of
23.9% (38.0 6 17.2 mm; P < 0.01) was achieved (Fig. 1C). At
the end of the follow-up period 72% of the patients showed
some degree of response to therapy, with a mean VL decrease
of 35.7%.
Vessel Caliber. Vessel caliber did not experience significant
changes at any of the time points studied: 4.1% at week 3
(0.0005 6 0.0004 mm; P¼ 0.32), 5.0% (0.0006 6 0.0004 mm;
P¼ 0.26) at week 7, and 2.3% (0.0003 6 0.0005 mm; P¼ 0.62)
by week 12 (Fig. 1D). At the end of the follow-up period 33% of
the patients showed some reduction of VC, with a mean
decrease of 15.0%.
FIGURE 1. Percentage of change in neovascular area (A), invasion area (B), total vessel length (C), and average vessel caliber (D) in response to topical
pazopanib at the studied time points. At the end of follow-up period the mean reduction was 22.4% (mean 6 SE [1.5 6 0.8 mm2; P ¼ 0.03]) for
neovascular area, 13.3% (3.9 6 1.8 mm2; P¼ 0.04) for invasion area, 23.9% (38.0 6 17.2 mm; P < 0.01) for vessel length, and 2.3% (0.0003 6 0.0005
mm; P¼ 0.62) for vessel caliber. Reduction of neovascularization was statistically significant for all metrics except for vessel caliber. Wk, weeks.
TABLE 3. Safety Parameters before and at the Time of Treatment Discontinuation
Baseline, mean 6 SD End of Treatment, mean 6 SD P Value of Change
Systemic
Mean arterial pressure, mm Hg 92.0 6 1.7 90.7 6 1.4 0.44
Heart rate, bpm 70.4 6 8.1 68.7 6 7.6 0.46
Ocular
IOP, mm Hg 15.7 6 5.9 16.9 6 5.3 0.23
Pachymetry, microns 572 6 135 590 6 162 0.89
Visual acuity, decimal 0.55 0.65 0.74
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FIGURE 2. Effect of topical pazopanib before (left) and after treatment (right). Superior panels (1, 3) show the clinical images, and the inferior
panels (2, 4) depict neovessels traced from the images above. (A) A 35-year-old man with history of recurrent herpetic keratouveitis complicated
with corneal neovascularization. (B) A 41-year-old man with history of firework injury and corneal transplantation complicated with fungal keratitis
and extensive corneal neovascularization.
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CONCLUSIONS
VEGF and PDGF play critical roles in corneal neovasculariza-
tion. These molecules activate homologous receptors to
VEGFRs and PDGFRs.11–14,17–22 Blockade of VEGF signaling
suppresses vascular endothelial cell migration, proliferation,
and survival.36 Pazopanib, a multi-targeted receptor kinase
inhibitor, blocks phosphorylation signaling induced by ligand
binding to these receptors.27 The present study shows that
topical pazopanib is safe and well tolerated, and can effectively
reduce established CNV as measured by invasion area, vessel
length, and neovascular area.29
Treatment with topical pazopanib led to a 22% decrease of
corneal neovessels (NA) and NA is a function of vessel caliber
and length. In this study reduction in NA and VL were
equivalent; however, reduction in VC was not equivalent to
reduction in either NA or VL. Our results show that VC
changed minimally after treatment and remained stable
throughout the study. Based on this, we could postulate that
treatment with topical pazopanib is more effective at reducing
vessel length than vessel caliber, as opposed to treatment with
topical bevacizumab as reported by us.35
VEGFR blockade disrupts endothelial cell migration and
proliferation.36 In CNV, pericyte recruitment lags days to
weeks behind establishment of new vessels.37 PDGF receptor-
signaling blockade impairs pericyte recruitment and results in
pericyte detachment from new coated vessels.38 Pericyte
detachment makes neovessels more susceptible to downregu-
lation of angiogenic responses (VEGFR blockade by pazopanib)
and leads to regression of ‘‘naked’’ vessels. Therefore, the early
(week 3) reduction in NA, IA, and VL seen with pazopanib
treatment may be due to the effect of VEGF-R blockade and
subsequent regression of new immature and naked vessels.
The delayed response (week 12) may be the result of impaired
proliferation and pericyte detachment in stable vessels.
Measurement of vessel leakage is a subjective parameter,
and is mostly evaluated clinically. In this study, two patients
showed clinically significant reduction in corneal exudates
throughout the study. This finding is similar to those reported
by Thakur et al.34 in the retina after treatment with pazopanib.
We excluded these 2 patients from the statistical analysis since
we considered them to be clinically improved, although new
vessels were revealed (which were obscured previously) in the
areas with reduced exudates after the treatment.
It has been reported that patients receiving oral pazopanib
are more likely to develop mild to moderate increases in blood
pressure and liver function tests, transaminase or thyroid
stimulating hormone levels.39 In order to minimize the risk of
systemic drug absorption lacrimal puncta were occluded in all
participants in our study. We did not observe severe ocular or
systemic adverse events during the study. Systemic blood
pressure and heart rate, parameters of clinical interest when
using anti-VEGF agents, remained stable throughout the study.
Topical pazopanib was well tolerated as measured by patients’
symptoms, and there were no episodes of corneal epitheliop-
athy, thinning, or other ocular side effects.
A limiting factor of this pilot study, whose main objective was
to assess safety, included the lack of a control group and
randomization. Another limitation was the heterogeneity of
baseline CNV in our cohort. We included patients with different
degrees of CNV from different causes, which may have limited
our ability to identify the effect of topical pazopanib in specific
clinical scenarios. This factor may also have limited the capacity
of pazopanib to achieve higher average NV reduction (i.e., lack
FIGURE 3. Effect of topical pazopanib before (left) and after treatment (right). Superior panel shows the clinical images and inferior panel depicts
neovessels traced from the images above. A 29-year-old man with chronic Stevens-Johnson syndrome and severe dry eye complicated with corneal
neovascularization showing only a modest response to treatment with topical pazopanib.
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of change in very severe or chronic CNV cases). Overall, patients
with newer or less severe CNV responded more favorably to
treatment (Figs. 2A–B), while some severe and chronic cases
experienced only a modest response (Fig. 3). Since the purpose
of this study was mainly recognition of possible adverse effects
of topical pazopanib, we prioritized the number of subjects over
the specific characteristics of the population. A longer follow-up
after treatment may have helped us to recognize further
reduction in CNV, as shown by our group with the use of
topical bevacizumab.35
In summary, the results of this study indicate that topical
treatment with pazopanib 0.5% leads to a statistically significant
reduction in CNV based on decrease in NA, VL, and IA. Our
results also suggest that CNV can remain stable or even continue
regressing after discontinuation of the treatment. In this study,
there were no reports of severe adverse effects in treatment
with topical pazopanib that would preclude continued investi-
gation. This leads us to conclude that topical pazopanib, at the
dose and duration used in this study, is safe, well tolerated, and
may have a role as an adjunctive approach to conventional
therapy for the treatment of CNV. Additional prospective,
randomized trials may be needed to further evaluate the safety
and efficacy of topical pazopanib and to determine the ideal
dosage and duration of therapy.
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